Current and Potential Approaches for Defining Disease Signatures: a Systematic Review
- 61 Downloads
Identifying disease signatures in order to facilitate accurate diagnosis/treatment has been the focus of research efforts in the last decade. However, the term “disease signature” has not been properly defined, resulting in inconsistencies between studies, as well as limited ability to fully utilize the tools/information available in the evolving field of healthcare big data. Research was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines. The search (in PubMed, Cochrane, and Web of Science) was limited to English articles published up to 31/12/2016. The search string was “disease signature” OR “disease signatures” OR “disease fingerprint” OR “disease fingerprints” OR “subtype signature” OR “subtype signatures” OR “subgroup signature” OR “subgroup signatures.” The full text of the articles was reviewed to determine the meaning of the phrase “disease signature” as well as the context of its use. Of 285 articles identified in the search, 129 were included in the final analysis. The term disease signature was first found in an article from 2001. In the last 10 years, the use of the term increased by approximately ninefold, which is double the general increase in the number of published articles. Only one article attempted to define the term. The two major medical fields where the term was used were oncology (31%) and neurology (20%); 71% of the identified articles used a single biomarker to define the term, 13% of the articles used a pair of biomarkers, and 16% used signatures with multiple biomarker; in 42% of the identified articles, genomic biomarkers were used for the signature, in 17% measurements of biochemical compounds in body fluids, and in 10%, changes in imaging studies were used for the signature. Our findings identified a lack of consistency in defining the term disease signature. We suggest a novel hierarchical multidimensional concept for this term that would combine both current approaches for identifying diseases (one focusing on undesired effects of the disease and the other on its causes). This model can improve disease signature definition consistency which will enable to generalize and classify diseases, resulting in more precise treatments and better outcomes. Ultimately, this model could lead to developing a statistical confidence in a disease signature that would allow physicians/patients to estimate the precision of the diagnosis, which, in turn, may have important implications on patients’ prognosis and treatment.
KeywordsDisease signature Systematic review Parkinson’s disease
Preferred Reporting Items for Systematic Review and Meta-analyses
We thank Shiri Diskin, PhD, for her editorial assistance in manuscript preparation.
This work was performed in partial fulfillment of the M.D. thesis requirements of the Sackler Faculty of Medicine, Tel Aviv University.
The research leading to these results has received funding from the European Union Seventh Framework Program (FP7/2007-2013) under grant agreement no. 604102 (Human Brain Project).
- American Psychiatric Association. (2013). Schizophrenia spectrum and other psychotic disorders. In: Diagnostic and statistical manual of mental disorders. Arlington, Va. https://doi.org/10.1176/appi.books.9780890425596.dsm02
- (2017) First tissue-agnostic drug approval issued. Cancer Discov. 7:656. https://doi.org/10.1158/2159-8290.CD-NB2017-078
- Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R (2015) Breast cancer risk reduction, version 2.2015. J Natl Compr Cancer Netw 13:880–915. https://doi.org/10.6004/JNCCN.2015.0105 CrossRefGoogle Scholar
- Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL (2009) The cortical signature of Alzheimer’s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19:497–510. https://doi.org/10.1093/cercor/bhn113 CrossRefGoogle Scholar
- Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE (2017) Biomarker-driven phenotyping in Parkinson’s disease: a translational missing link in disease-modifying clinical trials. Mov Disord 32:319–324. https://doi.org/10.1002/mds.26913 CrossRefGoogle Scholar
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34. https://doi.org/10.1016/j.jclinepi.2009.06.006 CrossRefGoogle Scholar
- Medicine U.S. National Library of 2014 (2014) Statistical reports on MEDLINE®/PubMed® baseline data. http://www.nlm.nih.gov/bsd/licensee/baselinestats.html. Accessed 9 Dec 2018
- Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E, van Damme-Lombaerts R, Palcoux JB, Cachat F, Lavocat MP, Bourdat-Michel G, Nobili F, Cochat P (2009) Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 24:1525–1532. https://doi.org/10.1007/s00467-009-1138-5 CrossRefGoogle Scholar
- Metaxas O, Dimitropoulos H, Ioannidis Y, Paedigree M (2014) AITION: a scalable KDD platform for big data healthcare. In: IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI). IEEE, 345 E 47TH ST, NEW YORK, NY 10017 USA, pp 601–604Google Scholar
- Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N (2016) Arm swing as a potential new prodromal marker of Parkinson’s disease. Mov Disord 31:1527–1534. https://doi.org/10.1002/mds.26720 CrossRefGoogle Scholar
- Somme JH, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, Fernandez Martinez M, Zarranz JJ, Gómez-Esteban JC (2015) Cognitive and behavioral symptoms in Parkinson’s disease patients with the G2019S and R1441G mutations of the LRRK2 gene. Parkinsonism Relat Disord 21:494–499. https://doi.org/10.1016/j.parkreldis.2015.02.019 CrossRefGoogle Scholar
- Steinlein OK (2008) Genetics and epilepsy. Dialogues Clin Neurosci 10:29–38Google Scholar
- Tombak M (n.d.) Disease - what is it. [online] Starthealthylife.com. Available at: http://www.starthealthylife.com/page186.htm. Accessed 4 Jul 2016